NEW YORK (GenomeWeb News) – Companion diagnostics firm Oxford Cancer Biomarkers on Monday announced a biomarker discovery deal with AstraZeneca directed at an undisclosed drug.

Under the terms of the deal, OCB seeks to discover biomarkers that can predict responders and non-responders to the drug. OCB may also validate and further develop biomarkers resulting from the collaboration. AstraZeneca has the option to license the biomarkers.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.